Everything below concerns prohibited substance. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
== Medical uses == Antivenom is used to treat certain venomous bites and stings. They are recommended only if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the venomous species involved. In the US, approved antivenom, including for pit viper (rattlesnake, copperhead and water moccasin) snakebite, is based on a purified product made in sheep known as CroFab. It was approved by the FDA in October 2000. U.S. coral snake antivenom ceased production, and remaining stocks of in-date antivenom for coral snakebite expired in fall 2009, leaving the U.S. without a coral snake antivenom. However, as of July 2021, Pfizer has indicated that antivenom is available. Efforts are being made to obtain approval for a coral snake antivenom produced in Mexico which would work against U.S. coral snakebite, but such approval remains speculative. As an alternative when conventional antivenom is not available, hospitals sometimes use an intravenous version of the antiparalytic drug neostigmine to delay the effects of neurotoxic envenomation through snakebite. Some promising research results have also been reported for administering the drug nasally as a "universal antivenom" for neurotoxic snakebite treatment. A monovalent antivenom is specific for one toxin or species, while a polyvalent one is effective against multiple toxins or species. The majority of antivenoms (including all snake antivenoms) are administered intravenously; however, stonefish and redback spider antivenoms are given intramuscularly.
===== Strain promoted Huisgen cyclization of azides ===== Even though Staudinger ligation is a suitable bioconjugation in living cells without major toxicity, the phosphine's sensitivity to air oxidation and its poor solubility in water significantly hinder its efficiency. The copper(I) catalyzed azide-alkyne coupling has reasonable reaction rate and efficiency under physiological conditions, but copper poses significant toxicity and sometimes interferes with protein functions in living cells. In 2004, chemist Carolyn R. Bertozzi's lab developed a metal free [3+2] cycloaddition using strained cyclooctyne and azide. Cyclooctyne, which is the smallest stable cycloalkyne, can couple with azide through [3+2] cycloaddition, leading to two regioisomeric triazoles (Figure 12). The reaction occurs readily at room temperature and therefore can be used to effectively modify living cells without negative effects. It has also been reported that the installation of fluorine substituents on a cyclic alkyne can greatly accelerate the reaction rate.
=== Sport === Paul Frère (1917–2008), Belgian racing driver Wilfried Nancy (born 1977), football manager Jérôme Le Banner (born 1972), kickboxer and K-1 fighter Vikash Dhorasoo, (born 1973), international footballer Olivier Davidas (born 1981), footballer Dimitri Dragin (born 1984), judoka Julien Faubert (born 1983), footballer Kevin Anin (born 1986), footballer Gueïda Fofana (born 1991), footballer Jaylen Hoard (born 1999), French-American basketball player for Hapoel Tel Aviv Dan Delaunay (born 1995), professional footballer.
== 19th Century == 1848: Maria Mitchell became the first woman elected to the American Academy of Arts and Sciences; she had discovered a new comet the year before. 1850: Margaretta Morris and Maria Mitchell became the first women elected to the American Association for the Advancement of Science. Morris was a renowned entomologist who specialized in agricultural pests and water beetles, the latter of which was cited by Charles Darwin in his novel On the Origin of Species. 1853: Jane Colden was the only female biologist mentioned by Carl Linnaeus in his masterwork Species Plantarum. 1889: Mary Emilie Holmes became the first female Fellow of the Geological Society of America. 1889: Susan La Flesche Picotte became the first Native American woman to become a physician in the United States. 1893: Florence Bascom became the second woman to earn her Ph.D. in geology in the United States, and the first woman to receive a Ph.D. from Johns Hopkins University. Geologists consider her to be the "first woman geologist in this country [America]." 1896: Florence Bascom became the first woman to work for the United States Geological Survey.
== History == A digital ion trap (DIT) is an ion trap having a trapping waveform generated by the rapid switching between discrete high-voltage levels. The timing of the high voltage switch is controlled precisely with digital electronic circuitry. Ion motion in a quadrupole ion trap driven by a rectangular wave signal was theoretically studied in 1970s by Sheretov, E.P. and Richards, J.A. Sheretov also implemented the pulsed waveform drive for the quadrupole ion trap working in mass-selective instability mode, although no resonance excitation/ejection was used. The idea was substantially revisited by Ding L. and Kumashiro S. in 1999, where the ion stability in the rectangular wave quadrupole field was mapped in the Mathieu space a-q coordinate system, with the parameters a and q having the same definition as the Mathieu parameters normally used in dealing with sinusoidal RF driven quadrupole field. The secular frequency dependence on the a, q parameters was also derived thus the foundation was laid for many modern ion trap operation modes based on the resonance excitation. Also, in 1999, Peter T.A. Reilly began trapping and subsequently ablating and mass analyzing the product ions from nanoparticles obtained from car exhaust with a primitive hybrid square wave/sine wave driven 3D ion trap. In 2001 Reilly attended the 49th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Applied Topics where he presented his nanoparticle mass analysis work and met Li Ding for the first time.
Sources: en.wikipedia.org
Valve struggled to find a publisher, as many believed Half-Life was too ambitious for a first-time developer. Sierra On-Line signed Valve for a one-game deal as it was interested in making a 3D action game, especially one based on the Quake engine. Sierra gave Valve an advance of around $1 million in exchange for 30% of the revenue and 100% of the intellectual property; the rest of development was funded by Newell and Harrington. Valve first showed Half-Life in early 1997; it was a success at E3 that year, where Valve demonstrated the animation and artificial intelligence. Novel features of the artificial intelligence included fear and pack behavior. Valve aimed for a November 1997 release to compete with Quake II. By September 1997, the team found that, while they had built some innovative aspects in weapons, enemies, and level design, the game was not fun and there was little design cohesion. Playtesting produced "lukewarm" responses. Sierra would not agree to extra funding, so Newell took out a loan to fund additional development to rework the game and delay its release date. Valve took a novel approach of assigning a small team to build a prototype level containing every element in the game and then spent a month iterating on the level. When the rest of the team played the level, which the designer Ken Birdwell described as "Die Hard meets Evil Dead", they agreed to use it as a baseline. The team developed three theories about what made the level fun.
== Industrial requirements for an extracting agent == The European experience in nuclear partitioning led to advanced hydrometallurgical separation processes. However, the feasibility of these advanced partitioning processes at industrial level relies on the use of reliable and affordable extracting agents, which have to meet these relevant industrial requirements:
=== Infrastructure === As Minister, McNaughton introduced Bill 32, the Access to Natural Gas Act, in the fall of 2018. It was passed into law that December. Bill 32 was intended to make it possible to expand access to natural gas throughout rural and Northern Ontario, including First Nations communities. Premier Ford said in a statement released on September 17, 2018, that "cancelling the cap-and-trade carbon tax" had caused the price of natural gas to decrease in Ontario. Premier Ford announced the new legislation and explained how it differed from the previous government's 2017 taxpayer-funded $100 million Natural Gas Grant Program—through which—according to Premier Ford, "private sector companies were limited from participating in natural gas expansion, portions of which were instead managed by the [Natural Gas Grant Program]." Bill 32, the Access to Natural Gas Act passed into law in 2018 to "encourage more private gas distributors to partner with communities to develop projects that expand access to affordable and efficient natural gas." On September 18, 2018, the city of North Bay learned that the Natural Gas Grant Program funding of over $8.6 million had been cancelled for a natural gas project that would have extended "services to as many as 350 homes in the north shore area of Trout Lake." In January 2019, Minister McNaughton announced that the Ford government would provide $27 million to Northeast Midstream towards the construction of their Nipigon LNG gas plant.
== Research Contributions == GeneDx researchers have contributed to peer-reviewed publications in major scientific and medical journals, generating critical data to expand access to genomic testing. In 2020, GeneDx researchers co-authored a study published in Nature analyzing data from 31,058 exome trios to identify 28 previously undescribed genes associated with developmental disorders, providing diagnoses for approximately 500 families. A 2021 study in JAMA, using data from GeneDx, found that exome sequencing identified pathogenic or likely pathogenic variants in 32.7% of pediatric patients with cerebral palsy, providing evidence to support genetic testing guidelines for the condition. In 2025, GeneDx collaborated with Seattle Children's and the University of Washington on the SeqFirst research program, which produced two landmark publications. The SeqFirst-Neo study, published in the American Journal of Human Genetics, found that applying broad exclusion criteria for rapid genome sequencing in NICUs increased the odds of a precise genetic diagnosis ninefold compared to conventional care, with 42% of diagnosed infants having been missed under standard protocols. A companion study published in The Journal of Pediatrics demonstrated that implementing rapid genome sequencing as a first-tier test in non-critical pediatric inpatient wards reduced the average time to a precise genetic diagnosis from 289 days to 13 days.
RNA, in contrast, forms large and complex 3D tertiary structures reminiscent of proteins, as well as the loose single strands with locally folded regions that constitute messenger RNA molecules. Those RNA structures contain many stretches of A-form double helix, connected into definite 3D arrangements by single-stranded loops, bulges, and junctions. Examples are tRNA, ribosomes, ribozymes, and riboswitches. These complex structures are facilitated by the fact that RNA backbone has less local flexibility than DNA but a large set of distinct conformations, apparently because of both positive and negative interactions of the extra OH on the ribose. Structured RNA molecules can do highly specific binding of other molecules and can themselves be recognized specifically; in addition, they can perform enzymatic catalysis (when they are known as "ribozymes", as initially discovered by Tom Cech and colleagues).
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.